Halozyme Therapeutics (HALO) Stock Forecast & Price Target

$58.26 -0.35 (-0.60%)

(As of 12:35 PM ET)

Halozyme Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
4

Buy
6

Based on 10 Wall Street analysts who have issued ratings for Halozyme Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 4 have given a hold rating, and 6 have given a buy rating for HALO.

Consensus Price Target

$61.11
4.89% Upside

According to the 10 analysts' twelve-month price targets for Halozyme Therapeutics, the average price target is $61.11. The highest price target for HALO is $73.00, while the lowest price target for HALO is $49.00. The average price target represents a forecasted upside of 4.89% from the current price of $58.26.

HALO Analyst Ratings Over Time

Type	Current Forecast 11/15/23 to 11/14/24	1 Month Ago 10/16/23 to 10/15/24	3 Months Ago 8/17/23 to 8/16/24	1 Year Ago 11/15/22 to 11/15/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$61.11	$60.44	$59.44	$52.73
Forecasted Upside	4.89% Upside	12.31% Upside	0.04% Upside	34.03% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Is Your 401(k) Safe? The Real Risk No One Sees Coming (Ad)

Every day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.

Click Here For Your Free Guide

HALO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HALO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Halozyme Therapeutics Stock vs. The Competition

Type	Halozyme Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.60	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	4.27% Upside	25,287.73% Upside	8.04% Upside
News Sentiment Rating	Positive News See Recent HALO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/4/2024	Piper Sandler 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$51.00 ➝ $52.00	-11.76%
11/1/2024	JMP Securities 2 of 5 stars		Boost Target	Market Outperform ➝ Market Outperform	$72.00 ➝ $73.00	+28.18%
11/1/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$65.00 ➝ $68.00	+34.47%
10/18/2024	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
10/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$58.00 ➝ $62.00	+7.30%
9/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$52.00 ➝ $57.00	-8.52%
Is Your 401(k) Safe? The Real Risk No One Sees Coming (Ad) Every day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes. Click Here For Your Free Guide
8/8/2024	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00	+9.55%
8/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$59.00 ➝ $65.00	+20.10%
8/7/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$59.00 ➝ $64.00	+16.60%
7/22/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$44.00 ➝ $49.00	-9.02%
3/27/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$58.00	+68.16%
3/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$42.00	+16.44%
3/16/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$42.00	+4.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:59 PM ET.

HALO Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Halozyme Therapeutics is $61.11, with a high forecast of $73.00 and a low forecast of $49.00.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
: According to analysts, Halozyme Therapeutics's stock has a predicted upside of 4.89% based on their 12-month stock forecasts.
: Over the previous 90 days, Halozyme Therapeutics's stock had 2 downgrades by analysts.
: Halozyme Therapeutics has been rated by research analysts at Cowen, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Piper Sandler, and Wells Fargo & Company in the past 90 days.
: Analysts like Halozyme Therapeutics less than other "medical" companies. The consensus rating score for Halozyme Therapeutics is 2.60 while the average consensus rating score for "medical" companies is 2.80. Learn more on how HALO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Is Your 401(k) Safe? The Real Risk No One Sees Coming (Ad)

Click Here For Your Free Guide

This page (NASDAQ:HALO) was last updated on 11/14/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Stock Forecast & Price Target